Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients.
about
Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature.Chloroquine inhibits Ca2+ permeable ion channels-mediated Ca2+ signaling in primary B lymphocytesNew concepts in antimalarial use and mode of action in dermatology.Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management.Aortic Atherosclerosis in Systemic Lupus ErythematosusAntiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeysClinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus.Targeting the inflammasome in rheumatic diseases.Association of γδ T Cell Compartment Size to Disease Activity and Response to Therapy in SLE.Analysis of the Expression and Function of Immunoglobulin-Like Transcript 4 (ILT4, LILRB2) in Dendritic Cells from Patients with Systemic Lupus Erythematosus.Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris.Cytokines and their receptors as biomarkers of systemic lupus erythematosus.Inflammasomes in Myeloid Cells: Warriors Within.IL-10 and TNFalpha genotypes in SLE.Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.Pharmacogenetics: implications for therapy in rheumatic diseases.The role of antimalarial agents in the treatment of SLE and lupus nephritis.New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.Treatment of severe lupus nephritis: the new horizon.Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study.Immunosenescence and hurdles in the clinical management of older HIV-patients.Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC.Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection.Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark.Hungry for more: autophagy in the pathogenesis of pulmonary arterial hypertension.
P2860
Q33315696-C1C57591-65AB-43CC-804E-21104FE05951Q33721657-5FFE1064-4E10-409D-A4BA-E85FB089BB89Q34007922-332A4F24-78E2-4633-B96E-4B6AA7EC5EA5Q34106220-13C32087-1961-49F3-9B5A-F36AD1241DA4Q34446781-80E9695E-BCAD-4056-A263-3B9D5F461456Q34476952-28961FAE-9DBE-4BD4-A256-3490ED2C75B8Q34938841-31221F70-8EF1-4F26-9CDB-6BC9AF4835FCQ35324935-4D7FBFFE-A92B-43E7-B162-1E1C442AB375Q35743904-88BF13B9-1DAF-4392-ACD2-F31D288A0DF1Q35804717-F876B799-ED1C-4CF9-917F-FD772B39DFC9Q36059097-BCCA4F6F-E9B0-4969-AA47-9A9D7A4BB5A5Q36656237-6C542083-BC96-4DD1-BB7B-A23A486C4316Q36731758-C9AF28D9-B8C0-409C-92BF-C2BA5B45594DQ37118987-647F4813-7372-433B-843E-E79362F8BD40Q37607695-5CEFAB9A-806D-409A-AA2D-D73FA2FE69AAQ37772082-15AFE76D-B297-4109-A1C8-E17B046F8AA2Q37854742-8A89A766-31B4-4F82-A0E8-7E6E0F0CCAFBQ37913989-DF5B917A-E22A-45E9-890A-3F8BF2092482Q37947108-94749F7A-B145-495B-8D81-BF1375445CCEQ38026787-A0E8FA23-82D3-459F-9F9D-4F1C9016DA7CQ38029146-D79CF77C-50DE-430C-9D5B-5BF6170D98DDQ38271125-57952782-17E7-4A01-99B5-2CA6941E1A69Q38311906-654317B8-49CD-479C-89CF-6CFAE598CDCBQ38557048-749F3C9B-55C5-4886-9270-0B97E4D3E0E3Q39039141-11445ECF-4BBD-40E0-8D97-849F1746C460Q39144641-526001D3-7F36-4300-9B12-13D669578380Q39170367-BC47BC7B-238E-4AE6-8CFD-7A1572885E68Q39420155-39EB03B1-1A4E-4F81-87FB-393A843BB7F3Q40218594-BD5D49DB-A35A-45DE-B84D-860B043822F7Q41919852-3604A642-E6AD-4BF7-8ECC-EAE8FE22D88DQ43067570-7221FF4A-1C1E-4989-972D-4FB0E7E06593
P2860
Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chloroquine treatment influenc ...... lupus erythematosus patients.
@en
type
label
Chloroquine treatment influenc ...... lupus erythematosus patients.
@en
prefLabel
Chloroquine treatment influenc ...... lupus erythematosus patients.
@en
P2093
P2860
P1433
P1476
Chloroquine treatment influenc ...... lupus erythematosus patients.
@en
P2093
A Sysa-Jedrzejowska
A Wozniacka
D P McCauliffe
P2860
P304
P356
10.1191/0961203306LU2299OA
P577
2006-01-01T00:00:00Z